Abstract 168P
Background
Routine genomic profiling in metastasic solid tumors has an impact on survival by selecting targeted therapies and montoring treatment response. Moreover, feasibility and efficiency of liquid biopsy (LB) in pancreatic cancer has been studied as tissue is not always available in these tumors given the frequent lack of tissue in these tumors.
Methods
We present an ambispective observational study in patients with locally advanced or metastatic pancreatic cancer who underwent LB before starting chemotherapy. The primary end point was to determine the prevalence of pathological molecular alterations in circulating tumor DNA (ctDNA) and their concordance with next generation sequencing in tumor tissue (TNGS). A secondary end point was the study of circulating tumor cells (CTCs) as a poor prognostic factor for survival.
Results
A total of 30 patients were included between May 2020 and September 2022. Women were 53.3% of them, and the median age was 65.5 years (37-85). At the time of LB, 86.7% had metastatic disease, 6.7% had stage III, and 6.7% had stage II. 83.4% were about to initiate a first-line chemotherapy. 86.7% of the patients had also undergone TNGS. In both LB and TNGS, one or more molecular alterations were found in 80% of patients. Fourteen different molecular alterations were found in LB, with the most prevalent mutations in TP53 (56.6%), KRAS (53.3%), ERBB2 (16.6%), MET (4%), and EGFR (4%). In TNGS, 12 alterations were found, with the most prevalent being TP53 (46.6%), KRAS (60%), MET (23.3%), and EGFR (13.3%). The concordance rate between BL and TNGS was > 70%. The median overall survival (OS) was 5.5 months (95%CI:3.6-7.4). In patients without CTCs, the OS was 6.3 months (95%CI:4.7-8.0), while patients with CTCs had an OS of 3.6 months (95%CI:1.6-5.6).
Conclusions
80% of patients presented molecular alterations in both LB and TNGS with a matching rate > 70%. The most prevalent mutations were TP53, KRAS, MET, EGFR and ERBBE in the two analyses. The presence of CTCs is a poor prognostic factor.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract